Table 1. Baseline clinical characteristics of patients with Pneumocystis jirovecii, candidemia, chronic disseminated candidiasis, invasive aspergillosis, mucormycosis, and TB, and of healthy volunteers.
| Variable | PCP (n = 50) a |
Candidemia (n = 15) |
CDC (n = 6) b |
Aspergillosis (n = 15)c |
Mucormycosis (n = 10)d |
TB (n = 20)e |
Healthy volunteers (n = 20) |
|---|---|---|---|---|---|---|---|
| Age, years, median (IQR) | 54 (43–68) | 65 (52–73) | 54 (36–67) | 58 (50–66) | 57 (48–65) | 61 (46–72) | 32 (30–43) |
| Male gender | 31 (62) | 10 (67) | 4 (67) | 8 (53) | 4 (40) | 11 (55) | 8 (40) |
| Underlying condition or illness | |||||||
| Diabetes | 14 (28) | 1 (7) | 1 (17) | 2 (13) | 4 (40) | 1 (5) | 0 (0) |
| Solid tumor | 3 (6) | 10 (67) | 0 (0) | 3 (20) | 0 (0) | 0 (0) | 0 (0) |
| Hematologic malignancy | 20 (40) | 0 (0) | 6 (100) | 8 (53) | 6 (60) | 3 (15) | 0 (0) |
| Chronic renal failure | 10 (20) | 0 (0) | 0 (0) | 1 (7) | 1 (10) | 4 (20) | 0 (0) |
| Rheumatologic disease | 5 (10) | 1 (7) | 0 (0) | 1 (7) | 0 (0) | 0 (0) | 0 (0) |
| Transplantation | 20 (40) | 0 (0) | 1 (17) | 4 (27) | 5 (50) | 1 (5) | 0 (0) |
| Liver cirrhosis | 2 (4) | 3 (20) | 0 (0) | 0 (0) | 1 (10) | 2 (10) | 0 (0) |
| Neutropenia (ANC<500) | 0 (0) | 0 (0) | 0 (0) | 1 (7) | 3 (30) | 0 (0) | 0 (0) |
| No underlying disease | 0 (0) | 0 (0) | 0 (0) | 1 (7) | 0 (0) | 2 (20) | 20 (100) |
| Immunosuppressive conditionf | 50 (100) | 15 (100) | 6 (100) | 13 (87) | 10(100) | 9 (45) | 0 (0) |
Abbreviations: PCP, Pneumocystis pneumonia; CDC, chronic disseminated candidiasis; TB, tuberculosis; IQR, interquartile range; ANC, absolute neutrophil count
Data are no. (%) patients unless otherwise indicated.
aIncludes 47 non-HIV patients and 3 HIV patients.
bIncludes 2 proven and 4 probable CDC
cIncludes 6 proven and 9 probable aspergillosis.
dIncludes 8 proven and 2 probable mucormycosis.
eIncludes 3 pulmonary TB, 9 disseminated TB, 5 TB lymphadenopathy and 3 TB peritonitis.
fImmunosuppressive condition is defined as underlying disease such as malignancy, liver cirrhosis and chronic renal failure, and/or patients who were receiving immunosuppressive treatment.